Company Description
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.
The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.
In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder.
It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries.
The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited.
DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Sep 28, 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Dr. James E. Brown D.V.M. |
Contact Details
Address: 10240 Bubb Road Cupertino, California 95014 United States | |
| Phone | (408) 777-1417 |
| Website | durect.com |
Stock Details
| Ticker Symbol | DRRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001082038 |
| CUSIP Number | 266605104 |
| ISIN Number | US2666055007 |
| Employer ID | 94-3297098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James E. Brown D.V.M. | Co-Founder, Chief Executive Officer, President and Director |
| Timothy M. Papp M.B.A. | Chief Financial Officer and Secretary |
| Dr. Norman L. Sussman M.D. | Chief Medical Officer |
| Judy R. Joice | Senior Vice President of Operations and Corporate Quality Assurance |
| Dr. WeiQi Lin M.D., Ph.D. | Executive Vice President of Research and Development and Principal Scientist |
| Keith L. Lui M.B.A. | Senior Vice President of Business Development, Commercial and Medical Affairs |
| Jian Li M.B.A. | Senior Vice President of Finance, Corporate Controller and Secretary |
| Dr. Su Il Yum Ph.D. | Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | 424B5 | Filing |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 22, 2023 | 8-K | Current Report |
| Dec 1, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |